This site is intended for healthcare professionals

Larotrectinib to treat advanced solid tumors that display a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, is submitted for marketing authorization in China.- Bayer

Read time: 1 mins
Published:27th May 2021

Larotrectinib is a highly selective TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion. The product is already approved in several countries under the brand name Vitrakvi, including the U.S., countries of the European Union (EU), and most recently Japan. Filings in other regions are underway or planned.

Condition: NTRK Fusion Cancers
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.